Gsk (GLAXF) Capital Expenditures (2009 - 2026)

Gsk's Capital Expenditures history runs 18 years deep, the most recent figure standing at -$297.9 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 13.73% year-over-year to -$297.9 million; the TTM figure through Mar 2026 stood at -$1.8 billion (down 4.81% YoY), while the FY2025 annual figure was $1.8 billion, down 0.61% from the prior year.
• Capital Expenditures was -$297.9 million for Q1 2026 at Gsk, up from -$762.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $3.2 billion in Q4 2022 to a low of -$1.6 billion in Q4 2023.
• Historically, Capital Expenditures has averaged -$243.1 million across 5 years, with a median of -$356.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures soared 352.24% in 2022, then slumped 150.49% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $3.2 billion in 2022, then plunged by 150.49% to -$1.6 billion in 2023, then jumped by 57.19% to -$698.2 million in 2024, then declined by 9.16% to -$762.2 million in 2025, then jumped by 60.91% to -$297.9 million in 2026.
• The last three Capital Expenditures figures came in at -$297.9 million (Q1 2026), -$762.2 million (Q4 2025), and -$419.7 million (Q3 2025), per Business Quant data.